# Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

> **NCT01861054** · PHASE2 · TERMINATED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Reparixin

## Key facts

- **NCT ID:** NCT01861054
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2015-03
- **Final completion:** 2016-03-01
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Enrollment target not reached
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861054, "Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01861054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*